Advertisement

Inpharma Weekly

, Volume 788, Issue 1, pp 8–8 | Cite as

DAB 486-IL-2

the first genetically engineered fusion toxin to enter phase I trials as an anticancer agent
Newsletter Article

Keywords

Chronic Lymphocytic Leukaemia Lymphocytic Leukaemia Partial Remission Interferon Gamma Diphtheria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1991

Personalised recommendations